Core Viewpoint - The stock of Fuhong Hanlin (02696) has seen a significant increase, with a rise of over 6% in early trading, attributed to recent developments including a stake increase by Point72 and FDA approvals for its biosimilar products [1] Group 1: Stock Performance - Fuhong Hanlin's stock rose by 5.09%, reaching HKD 79.45, with a trading volume of HKD 32.3344 million [1] - Point72, a hedge fund managed by Steve Cohen, increased its holdings in Fuhong Hanlin by 243,800 shares at an average price of HKD 83.5703 per share, investing approximately HKD 20.3744 million [1] - Following the purchase, Point72's total shareholding increased to 8.2379 million shares, raising its ownership percentage from 4.89% to 5.04% [1] Group 2: Product Approvals - Fuhong Hanlin announced that the U.S. FDA has approved the market applications for two biosimilar products: BILDYOS (denosumab-nxxp) and BILPREVDA (denosumab-nxxp) [1] - These products are biosimilars to PROLIA (denosumab) and XGEVA (denosumab) [1] - In 2022, Fuhong Hanlin entered into a licensing and supply agreement with Organon, granting Organon exclusive commercialization rights for several biosimilars, including BILDYOS and BILPREVDA, outside of China [1]
港股异动 | 复宏汉霖(02696)早盘涨超6% 股东Point72近期增持股份 公司旗下两款产品获FDA批准上市